Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Nirsevimab, Season 1
MMWR recomm. rep; 72 (34), 2023
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms of the long-acting monoclonal antibody nirsevimab, (Beyfortus, Sanofi and AstraZeneca) for prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract infecti...